Switch to:
Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Research and Development
$1,525 Mil (TTM As of Dec. 2015)

This is the expense the company spent on research and development. Teva Pharmaceutical Industries Ltd's research and development for the three months ended in Dec. 2015 was $446 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2015 was $1,525 Mil.


Definition

This is the expense the company spent on research and development.

Teva Pharmaceutical Industries Ltd Research & Development for the trailing twelve months (TTM) ended in Dec. 2015 was 332 (Mar. 2015 ) + 386 (Jun. 2015 ) + 361 (Sep. 2015 ) + 446 (Dec. 2015 ) = $1,525 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Teva Pharmaceutical Industries Ltd Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
Research & Development 4955812,1888029511,0951,3561,4271,4881,525

Teva Pharmaceutical Industries Ltd Quarterly Data

Sep13Dec13Mar14Jun14Sep14Dec14Mar15Jun15Sep15Dec15
Research & Development 348411353344412379332386361446
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GuruFocus Premium Plus Membership

FEEDBACK